JCR Pharmaceuticals Co Ltd 2021 Integrated Report
The report presents JCR Group's FY2020 performance, including record net sales of 30,085 million yen and the Japan approval and May 2021 launch of IZCARGO®. It describes JCR's contracted production of AstraZeneca's COVID-19 vaccine bulk solution and the construction of a new plant. Its sustainability coverage addresses rare diseases, environment, society, governance, SDG linkages, employee systems and environmental resource use.
Company: JCR Pharmaceuticals Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2021
Type: Integrated Report
Pages: 76
Back to company
JCR Pharmaceuticals Co Ltd
Jcr Report
The report presents JCR Group's FY2020 performance, including record net sales of 30,085 million yen and the Japan approval and May 2021 launch of IZCARGO®. It describes JCR's contracted production of AstraZeneca's COVID-19 vaccine bulk solution and the construction of a new plant. Its sustainability coverage addresses rare diseases, environment, society, governance, SDG linkages, employee systems and environmental resource use.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2020
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Women in Management
Employees